Estée Lauder Companies has taken a minority stake in 111Skin, the London-based clinical skincare brand known for its luxury serums and targeted treatments. The investment marks Lauder's continued expansion into prestige skincare as the conglomerate navigates potential merger discussions with Spanish beauty group Puig.
111Skin specializes in science-backed formulations featuring ingredients like hyaluronic acid, peptides, and proprietary complexes. The brand positions itself in the premium segment, with serums and moisturizers typically priced between $95 and $395. Founded by Christos Barnase andConstance Breuil, the brand has built a loyal following among dermatologists and aestheticians across North America and Europe.
This investment signals Lauder's appetite for acquiring stakes in high-growth, clinical skincare lines that appeal to consumers seeking efficacy-driven products. The move also strengthens Lauder's portfolio ahead of potential corporate restructuring. By backing 111Skin without acquiring full ownership, Lauder gains exposure to the brand's growth trajectory while maintaining flexibility around its broader portfolio strategy.
The deal underscores ongoing consolidation in the luxury skincare sector, where clinical positioning and ingredient transparency command premium pricing and consumer loyalty.